Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Tofacitinib Modified Release Formulations in Healthy Adults
NCT04338711Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tofacitinib oral solution in juvenile idiopathic arthritis (JIA) (6 arms), sponsored by Pfizer. Primary endpoints: Area Under the Curve From Time Zero to Extrapolated Infinite Time at 48 hours, Area Under the Curve From Time Zero to Last Quantifiable Concentration at 48 hours and 2 more. Started Jun 2020; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NCT04338711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04338711.